'/%3E%3C/svg%3E%0A){kind=small}
February 11 marks International Day of Women and Girls in Science. Last year, Donna-Lee Destouche, Head of Clinical Trial Management at Prothena, shared advice on inspiring the next generation of female leaders in STEM. Today, we’re honored to hear from Chi Johnson, Associate Director of Facilities and Environment Health & Safety (EH&S) at Prothena. Chi’s […]
The prevalence and impact of Alzheimer’s disease varies by sex, race and ethnicity. In fact, according to the Alzheimer’s Association, nearly two-thirds of people living with Alzheimer’s disease are women. Black Americans are nearly twice as likely as White Americans to develop Alzheimer’s disease or another dementia, and Hispanic Americans are 1.5 times as likely. […]
This summer we shared the powerful story of LuPita, currently living with dementia. Today we are honored to introduce Jessica, LuPita’s daughter and care partner, in honor of November marking National Family Caregivers Month. Hear firsthand from Jessica on how she decided to take on the vital role, the importance of taking care of oneself […]
This month, we’re excited to hear from the newest member of our leadership team at Prothena! In September, Chad Swanson was appointed as Prothena’s new Chief Development Officer. A neuropharmacologist with over 20 years industry experience, Chad joined Prothena as Senior Vice President and Head of Clinical Development in January 2023. In his new role, […]
Tomorrow marks World Amyloidosis Day, and we at Prothena are proud to join the Amyloidosis Alliance to help raise awareness of amyloidosis, a complex disease often misunderstood and misdiagnosed by medical professionals and unheard of by the general public. In the below video, Steve, living with AL amyloidosis, talks about the difficult and long journey […]
From running marathons to developing potential breakthrough treatments, for Christie it’s all about perseverance At Prothena, our mission is to bring life-changing therapies to patients battling neurodegenerative and rare peripheral amyloid diseases. Our clinical development efforts play a vital role in moving these therapies from early research to potential treatments that could improve the lives […]
Saturday, on World Alzheimer’s Day, we at Prothena joined Alzheimer’s Disease International to raise awareness of Alzheimer’s disease and challenge the stigma of this disease and other dementias. We recently shared the story of LuPita, currently living with dementia. Today, we are honored to help Phil tell his story. In another powerful tale, Phil underscores […]
Alzheimer’s disease is a devastating form of dementia that causes memory, thinking and behavior problems. It is believed two different proteins – Aβ (amyloid beta) and tau – are the primary contributors to its pathology. Misfolded Aβ builds up to form plaques between nerve cells in the brain. Tangles of twisted tau fibrils spread from […]
Earlier this year, we heard advice for people living with AL amyloidosis from an AL amyloidosis patient herself, Linda. Today, we continue to elevate firsthand perspectives of people directly impacted by this rare disease. Hear from Donna, a wife and mother, and caregiver to her husband Mike who is living with AL amyloidosis. She describes […]
Prothena is committed to developing novel and transformative medicines to create a better future for patients with neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. Before any treatment is made available to patients in the U.S., it must go through a rigorous set of clinical and nonclinical testing […]